Animal study results has been be presented by Prof. Bart Meuris during the Heart Valve Society (HVS) Meeting 2021
In-vivo Evaluation Of A Novel Surgical Heart Valve Prosthesis Designed To Be Durable, Anticoagulant-free And Silent.
Bart Meuris, Lucas Van Hoof, Wilm Decré, Marie Lamberigts, Tom Langenaeken, Peter Verbrugghe.
KU Leuven, Leuven, Belgium.
OBJECTIVE: Heart valves prostheses still face limitations: reoperations with tissue valves or lifelong anticoagulation with mechanical valves. The Triflo valve, a tri-leaflet valve made of high-resistant bio-inert materials, aimed at overcoming these limitations. We studied safety and performance in a chronic sheep model.
METHODS: The Triflo valve (size 21mm) was implanted in two models: 90 days in aortic position (n=7) and 70 days in pulmonary position (n=4). In the pulmonary model, On-X valves (n=2) were used as control. After 7 days of low-molecular-weight heparin, no further anticoagulant was administered. Serial blood testing, echocardiography, acoustic measurements, fluoroscopy and autopsy were done.
RESULTS: The Triflo valve demonstrated excellent surgical handling. There were one aborted procedure and one early death in the aortic study, both unrelated to the prosthesis. All other sheep (n=9) recovered fast and remained in excellent clinical condition until the scheduled sacrifice. In aortic position, we observed low peak and mean gradients (8.1+/-2.7 and 4.8+/-1.9 mmHg), high effective orifice area (2.3+/-0.2 cm2), no valvular regurgitation, and perfect left ventricular function. At explantation, the surface of all Triflo valves was clean, without any valve thrombosis. All major organs were free from thrombo-embolic (TE) damage. In pulmonary position, leaflet mobility of all valves remained also normal and no TE-damage was found in the lungs. Hematological parameters were stable without any sign of hemolysis. On-X valves in pulmonary position functioned well, but generated significantly louder acoustic signals (p<0.05).
CONCLUSIONS: The Triflo valve showed safety and effectiveness in both aortic and pulmonary position. These favorable in-vivo results, with excellent hemodynamic behavior and stable long-term function even in the absence of anticoagulants, demonstrate that this valve can proceed to first-in-human studies.
Related products
Customer comments
No comments were found for Animal study results has been be presented by Prof. Bart Meuris during the Heart Valve Society (HVS) Meeting 2021. Be the first to comment!